PET/MR User's Meeting: Technical challenges Feb 05, 2020 10:30 AM - 03:00 PM — Henry Wellcome Auditorium, 183 Euston Road, London
Scottish Ophthalmic Imaging Society meeting Feb 14, 2020 09:30 AM - 05:00 PM — Royal Society of Edinburgh, 22-26 George Street, Edinburgh
Scottish+ Radiotherapy Physics Meeting 2020 Feb 21, 2020 09:30 AM - 05:00 PM — Scottish Health Service Centre , Western General Hospital, Edinburgh
2nd Scottish Ultrasound Annual Scientific Meeting Feb 28, 2020 10:00 AM - 05:00 PM — Collins Building, University of Strathclyde
Technology Innovations for Healthcare Mar 12, 2020 09:00 AM - 05:00 PM — Royal College of Physicians, Edinburgh

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy

Author(s): B. R. Szwejkowski, S. J. Gandy, S. Rekhraj, J. G. Houston, C. C. Lang, A. D. Morris, J. George, A. D. Struthers

Abstract:
OBJECTIVES: This study sought to ascertain whether high-dose allopurinol causes regression of left ventricular mass (LVM) in patients with type 2 diabetes mellitus (T2DM). BACKGROUND: Left ventricular hypertrophy (LVH) is common in T2DM and contributes to patients' high cardiovascular (CV) event rate. Oxidative stress (OS) has been implicated in LVH development, and allopurinol has been previously shown to reduce vascular OS. We therefore investigated whether allopurinol causes regression of LVH in patients with T2DM. METHODS: We conducted a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM patients with echocardiographic evidence of LVH. Allopurinol, 600 mg/day, or placebo was given over the study period of 9 months. The primary outcome was reduction in LVM as calculated by cardiac magnetic resonance imaging at baseline and at 9 months' follow-up. Secondary endpoints were change in flow-mediated dilation and augmentation index. RESULTS: Allopurinol significantly reduced absolute LVM (-2.65 +/- 5.91 g vs. placebo group +1.21 +/- 5.10 g [p = 0.012]) and LVM indexed to body surface area (-1.32 +/- 2.84 g/m(2) vs. placebo group +0.65 +/- 3.07 g/m(2) [p = 0.017]). No significant changes were seen in either flow-mediated dilation or augmentation index. CONCLUSIONS: Allopurinol causes regression of LVM in patients with T2DM and LVH. Regression of LVH has been shown previously to improve CV mortality and morbidity. Therefore, allopurinol therapy may become useful to reduce CV events in T2DM patients with LVH. (Allopurinol in Patients with Diabetes and LVH; UKCRN 8766).

Full version: Available here

Click the link to go to an external website with the full version of the paper


ISBN: 1558-3597 (Electronic) 0735-1097 (Linking)
Publication Year: 2013
Periodical: J Am Coll Cardiol
Periodical Number: 24
Volume: 62
Pages: 2284-93
Author Address: Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom. Department of Clinical Radiology, Ninewells Hospital and Medical School, Dundee, United Kingdom. Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom; Department of Clinical Radiology, Ninewells Hospital and Medical School, Dundee, United Kingdom. Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom. Electronic address: j.george@dundee.ac.uk.